Hydrogel-Encapsulated Biofilm Inhibitors Abrogate the Cariogenic Activity of Streptococcus mutans .
Ahirwar, P., Kozlovskaya, V., Nijampatnam, B., Rojas, E.M., Pukkanasut, P., Inman, D., Dolmat, M., Law, A.C., Schormann, N., Deivanayagam, C., Harber, G.J., Michalek, S.M., Wu, H., Kharlampieva, E., Velu, S.E.(2023) J Med Chem 66: 7909-7925
- PubMed: 37285134 
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00272
- Primary Citation of Related Structures:  
8FG8 - PubMed Abstract: 
We designed and synthesized analogues of a previously identified biofilm inhibitor IIIC5 to improve solubility, retain inhibitory activities, and to facilitate encapsulation into pH-responsive hydrogel microparticles. The optimized lead compound HA5 showed improved solubility of 120.09 μg/mL, inhibited Streptococcus mutans biofilm with an IC 50 value of 6.42 μM, and did not affect the growth of oral commensal species up to a 15-fold higher concentration. The cocrystal structure of HA5 with GtfB catalytic domain determined at 2.35 Å resolution revealed its active site interactions. The ability of HA5 to inhibit S. mutans Gtfs and to reduce glucan production has been demonstrated. The hydrogel-encapsulated biofilm inhibitor ( HEBI ), generated by encapsulating HA5 in hydrogel, selectively inhibited S. mutans biofilms like HA5 . Treatment of S. mutans -infected rats with HA5 or HEBI resulted in a significant reduction in buccal, sulcal, and proximal dental caries compared to untreated, infected rats.
Organizational Affiliation: 
Department of Integrative Biomedical and Diagnostic Sciences, Oregon Health and Science University, Portland, Oregon 97239, United States.